Why Daridorexant Matters
Daridorexant is the third and newest dual orexin receptor antagonist (DORA), approved in January 2022 for adults with trouble falling asleep, staying asleep, or both. It blocks both orexin receptors, like suvorexant and lemborexant, and it has the shortest half-life of the three: about 8 hours, against roughly 12 for suvorexant and an effective 17 to 19 for lemborexant.
Its phase 3 program made daytime functioning a key secondary outcome. The two 3-month trials enrolled 1,854 adults, about 40% of them 65 or older. In the trial that tested it, 50 mg improved polysomnographic sleep onset and wake after sleep onset, self-reported total sleep, and the sleepiness domain of a validated daytime-symptom questionnaire (Mignot et al., Lancet Neurol 2022). The 25 mg dose helped sleep less consistently and did not significantly move the daytime score, and 10 mg failed. A 40-week extension found no new safety signals and no withdrawal or rebound after a year of nightly use.
Its interaction rules are easier to live with than lemborexant's. With a moderate CYP3A4 inhibitor such as diltiazem or fluvoxamine, the label allows 25 mg instead of saying avoid. Strong inhibitors and strong or moderate inducers are still off the table. It is brand-only, with no US generic as of November 2026. It is Schedule IV; an August 2026 DEA proposal to move the DORAs to Schedule V has not been finalized.
Use daridorexant when daytime fatigue is part of the complaint (a secondary outcome in the sponsor trials) or when a moderate CYP3A4 inhibitor rules out lemborexant. The trial evidence sits with 50 mg, older adults included; 25 mg is the dose when a moderate inhibitor or moderate liver impairment caps it. The short half-life does not make the first morning safe: its driving study showed impairment after the first 50 mg dose.
Part 1: Indications
FDA-Approved Use
- Insomnia in adults, characterized by difficulties with sleep onset and/or sleep maintenance
Nothing else is labeled, and safety and effectiveness have not been established in children.
The Evidence
Study 1 (Mignot et al., Lancet Neurol 2022). 930 adults with DSM-5 insomnia disorder (mean age 55, range 18 to 88, 39% aged 65 or older) took 50 mg, 25 mg or placebo for 3 months. Compared with placebo, 50 mg cut polysomnographic wake after sleep onset by 22.8 minutes at month 1 and 18.3 minutes at month 3, cut latency to persistent sleep by about 11 to 12 minutes, and added about 20 to 22 minutes of self-reported total sleep. It also improved the sleepiness domain of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) at both time points. The 25 mg dose improved wake time by about 12 minutes and sleep onset by about 8 minutes, with a smaller gain in total sleep, and missed significance on daytime sleepiness.
Study 2. 924 adults took 25 mg, 10 mg or placebo. The 25 mg dose improved wake after sleep onset (about 10 to 12 minutes) and self-reported total sleep (16 to 19 minutes), but sleep onset did not reach significance under the trial's testing rules. The 10 mg dose failed on every primary endpoint and is not an approved dose.
The 40-week extension (Kunz et al., CNS Drugs 2023). 804 patients from the two trials continued on their dose, with placebo patients re-randomized to 25 mg or placebo; 550 completed. Adverse events ran 35% to 40% across groups. There was no next-morning sleepiness signal and no withdrawal or rebound after stopping. In exploratory analyses, the improvement in daytime functioning scores on 50 mg held through week 36, while the gain in total sleep over placebo (about 16 to 20 minutes) had confidence intervals that crossed zero after week 12.
Older adults. In a secondary analysis of Study 1, 364 patients aged 65 or older got the same reductions in wake time and sleep onset as younger adults, and 50 mg improved daytime functioning in both age groups while 25 mg did so only in the younger group. Falls were less frequent on daridorexant than placebo, and there were no complex sleep behaviors or cataplexy in the older group (Fietze et al., Drugs Aging 2022). These are sponsor-run subgroup analyses.
Long-term evidence. The 2022 Lancet network meta-analysis (De Crescenzo et al.) found daridorexant effective in acute treatment, but its search ended in November 2021, before the extension data were published, so it had no long-term evidence to weigh.
Off-Label / Investigational
- Insomnia with nocturia. In a 4-week crossover trial of 60 adults aged 55 and older who voided at least 3 times a night, 50 mg added about 21 minutes of self-reported sleep and lowered Insomnia Severity Index scores by about 3 points. Night-time voids fell by 0.6 at week 1, but the difference was no longer significant at week 4. No falls or incontinence events were reported on drug (Lederer et al., J Sleep Res 2025). This is a small sponsor trial.
- Insomnia with psychiatric illness. The trials excluded acute or unstable psychiatric conditions, and there are no controlled daridorexant trials in depression or PTSD. A systematic review of the three DORAs in depression found consistent sleep gains but only modest effects on depressive symptoms, from mostly short studies (Vasudeva et al., J Psychiatr Res 2025). In substance use disorders the data are one retrospective series of 41 outpatients on 50 mg, with better sleep and good tolerability but no control group (Di Nicola et al., Pharmaceuticals 2025). Treat the comorbid disorder, and keep the label's depression and suicidality warning in mind.
Who Is a Good Candidate?
- A patient whose daytime fatigue and sleepiness are a big part of the complaint
- A patient on a moderate CYP3A4 inhibitor that cannot be changed (fluvoxamine, diltiazem, verapamil, fluconazole), at 25 mg
- An older adult who needs a hypnotic other than a Z-drug or benzodiazepine; the label sets no lower dose for age
- A patient who may need a hypnotic for months (the extension study ran 40 weeks after the 3-month trials)
Who Is a Poor Candidate?
- Narcolepsy, or a past allergic reaction to daridorexant (both contraindications)
- A patient on a strong CYP3A4 inhibitor, or a strong or moderate inducer such as carbamazepine or rifampin
- Severe hepatic impairment
- A patient who must drive early the morning after the first dose, or who cannot stay in bed 7 hours
- A patient for whom cost or prior authorization will end treatment
Part 2: Mechanism
Orexin neurons in the hypothalamus keep the wake-promoting transmitter systems (acetylcholine, dopamine, histamine, norepinephrine and serotonin) switched on. Daridorexant binds and blocks both orexin receptors with high affinity (Ki 0.47 nM at OX1R and 0.93 nM at OX2R), which is thought to suppress wake drive. The label describes no active metabolite.
Orexin also holds REM phenomena out of wakefulness, and narcolepsy with cataplexy is a disease of orexin-neuron loss. That is the reason for the narcolepsy contraindication and for the class side effects: sleep paralysis, hypnagogic and hypnopompic hallucinations, and brief cataplexy-like leg weakness. Single doses up to 200 mg in healthy volunteers produced cataplexy-like symptoms and sleep paralysis (Part 7).
Pharmacokinetics. Peak levels come 1 to 2 hours after a dose. A high-fat meal delayed the peak by 1.3 hours and cut Cmax by 16% without changing total exposure. Protein binding is 99.7% and the volume of distribution is small (31 L). CYP3A4 handles 89% of metabolism, and no other enzyme contributes more than 3%. The terminal half-life is about 8 hours, exposure is dose-proportional from 25 to 50 mg, and the drug does not accumulate with nightly dosing. Age, sex, race, body size and renal function made no clinically significant difference to exposure.
Daridorexant itself modestly raises the levels of some other drugs. Midazolam (a CYP3A4 substrate) and dabigatran (a P-gp substrate) rose about 1.4-fold. The QT interval was not prolonged to a clinically relevant extent at 4 times the maximum dose.
An 8-hour half-life with no accumulation means most of the drug should be gone by the end of a full night. The label still says CNS depressant effects can persist for up to several days after stopping, and the first-dose driving result in Part 6 is a reminder that pharmacokinetics alone do not predict who is impaired the next morning.
Part 3: Before You Start: Workup and Candidacy
No baseline labs are required by the label. Take a sleep and medication history.
| Check | Why it matters |
|---|---|
| Narcolepsy, cataplexy, sleep attacks | Contraindication. Ask about sudden weakness with laughter or surprise, and about sleep paralysis. |
| Allergy history | Hypersensitivity to daridorexant is a contraindication; angioedema with throat involvement has been reported after marketing. |
| Snoring, apneas, COPD | Short studies in mild to severe OSA and moderate COPD showed no meaningful change in apnea-hypopnea index or oxygen saturation, but mild and severe COPD were not studied and meaningful respiratory effects cannot be excluded, including with long-term use. |
| Depression and suicide risk | Labeled warning: hypnotics have been linked to worsening depression and suicidal thoughts in depressed patients. Monitoring and protective measures may be needed. |
| Substance use history | Schedule IV. At 2 to 3 times the maximum dose, drug liking matched zolpidem and suvorexant in recreational users. Follow closely. |
| Medication list | Strong CYP3A4 inhibitors or strong or moderate inducers: avoid. Moderate inhibitors: 25 mg maximum. Narrow-index CYP3A4 or P-gp substrates: caution. |
| Liver disease | Moderate impairment (Child-Pugh 7 to 9): 25 mg maximum. Severe (10 or more): not recommended. LFTs if liver disease is suspected (practice). |
| Morning driving and work | The label tells you to caution every patient on daridorexant against next-day driving and other tasks needing full alertness. |
| Pregnancy and breastfeeding | No human pregnancy data; very low transfer into milk. See Part 9. |
Offer CBT-I as well, or first. It is the recommended initial treatment for chronic insomnia (American College of Physicians guideline, Qaseem et al., Ann Intern Med 2016).
Part 4: How to Start and Dose
Adults over 65FDA labelNo dose adjustment is required in patients over the age of 65 years.In practiceThe trial evidence sits with 50 mg, older adults included; 50 mg was needed for the daytime-functioning benefit.
With CYP3A4 inhibitors or inducersFDA labelModerate inhibitors: 25 mg, no more than once per night. Strong inhibitors, and strong or moderate inducers: avoid.
Liver or kidney impairmentFDA labelModerate hepatic impairment (Child-Pugh 7 to 9): 25 mg maximum. Severe (10 or more): not recommended.
Switching from a benzo or Z-drug1 row
Stopping1 row
Dosing at a glance
| Situation | Label dose | Notes |
|---|---|---|
| Adults | 25 mg to 50 mg, no more than once per night | Within 30 minutes before going to bed, with at least 7 hours before planned waking |
| Maximum | 50 mg | Only 50 mg improved daytime sleepiness scores in the trials |
| Older adults | No dose adjustment | Somnolence and fatigue became more likely with age |
| Moderate CYP3A4 inhibitor | 25 mg, no more than once per night | Diltiazem raised exposure 2.4-fold |
| Strong CYP3A4 inhibitor | Avoid | Itraconazole is predicted to raise AUC by more than 400% |
| Strong or moderate CYP3A4 inducer | Avoid | Efavirenz cut exposure by about 60% |
| Moderate hepatic impairment | 25 mg maximum | Child-Pugh score 7 to 9 |
| Severe hepatic impairment | Not recommended | Child-Pugh 10 or more; not studied |
| Renal impairment | No adjustment | Including severe impairment not on dialysis |
| With food | No fixed rule | Sleep onset may be delayed if taken with or soon after a meal |
Formulations
Film-coated tablets, 25 mg (light purple) and 50 mg (light orange), arc-triangle shaped and unscored, in bottles of 30. Brand only (Quviviq, Idorsia).
Choosing a Dose
The label gives a range without a fixed starting dose. The trial evidence sits with 50 mg: it was the only dose that improved daytime sleepiness, it beat placebo on every primary and key secondary endpoint at both time points, and it had the more favorable numbers needed to treat in a sponsor analysis (Chalet et al., Postgrad Med 2024). Its adverse event rates were close to those of 25 mg. The 25 mg dose missed sleep onset in Study 2. Use 25 mg when a 25 mg rule applies: a moderate CYP3A4 inhibitor or moderate hepatic impairment. Whether to start at 25 mg in an older or sedation-sensitive patient is a judgment the label does not settle; the older-adult analysis found no age-related reason to lower the dose (Fietze et al., Drugs Aging 2022).
How to Take It
- In the evening, within 30 minutes before going to bed, once per night, and only with at least 7 hours left in bed.
- Not on a full stomach. A heavy meal delays the peak by over an hour, so sleep comes later and the peak shifts later into the night.
- No second dose after waking in the night. When volunteers were woken 4 hours after a dose, balance and memory were measurably worse than on placebo.
- No alcohol. Alcohol did not change daridorexant levels, but the combination added to impairment of balance and alertness.
Tell patients the first morning is the one to be careful about. In the driving study, impairment after the first 50 mg dose was statistically significant, and after four nights the average effect was no longer significant, though some subjects were still impaired. Keep the first dose for a night before a morning with no driving (practice, not label text).
Switching From a Z-Drug, Benzodiazepine or Trazodone
The label advises against combining daridorexant with other insomnia drugs and says other CNS depressants may need dose reductions. No randomized trial has tested a switch to daridorexant, so this plan rests on a consensus statement, a retrospective study and practice.
- After a week or two of a Z-drug or benzodiazepine: the 2026 German and Austrian sleep societies' consensus allows stopping abruptly after 1 to 2 weeks of use (Hajak et al., Dtsch Arztebl Int 2026); start daridorexant the next night (practice, not label).
- After months or years of nightly use: taper the old drug by 10% to 25% a week, more slowly after high doses or a year or more of use; the same consensus says overlapping daridorexant can ease withdrawal during the taper. That overlap is what the US label advises against, so keep the old dose falling and warn about next-morning sedation and falls. Adding suvorexant to a benzodiazepine receptor agonist, rather than switching, caused more oversedation and dropouts in a retrospective study of 228 patients (Hatano et al., Clin Psychopharmacol Neurosci 2018).
- Trazodone: the consensus tapers antidepressants used for sleep the same way after more than 2 weeks of use. Once daridorexant is working, do not keep trazodone as a second hypnotic (practice, not label).
Patients coming off a GABAergic hypnotic sometimes describe a DORA as subtler; that is clinical impression, untested in trials.
Missed dose
- One dose: if it is forgotten at bedtime, take it only if at least 7 hours remain before the patient has to be up; otherwise skip that night. Never two doses in one night (label: once per night, with 7 hours left before waking).
- Several days: no withdrawal is expected, but the insomnia can return from the first night off, as it did in the trials' placebo run-out.
- Restarting after a gap: restart at the usual dose, and after a long gap counsel as for a first dose (practice, not label).
What to tell the patient at the first prescription
- What to expect and when: sleep should improve over the first weeks, and in the trials the higher dose also eased daytime sleepiness.
- Early side effects: headache, and grogginess the morning after the first dose, so plan that first night before a morning with no driving. Some people briefly cannot move or speak as they fall asleep or wake, or see things that are not there; it passes, but tell me.
- Call me about: swelling of the face, lips or throat, hives or trouble breathing (stop it and get help), walking, eating or driving while not fully awake, sudden leg weakness, or worsening mood or thoughts of suicide.
- How to take it: within 30 minutes of bed, only with 7 or more hours to sleep, not on a full stomach, never a second dose in the night, and no alcohol.
- Next visit: about 7 to 10 days in; if sleep is no better by then, we look for another cause or adjust the dose (practice, not label).
Part 5: Monitoring
No levels and no routine labs. The label sets no schedule; this one is ordinary hypnotic practice.
| Parameter | Baseline | Follow-up |
|---|---|---|
| Next-morning alertness, driving | ✓ | First follow-up and after any dose change or new CYP3A4 drug |
| Response at 7 to 10 days | n/a | No remission: look for a medical or psychiatric cause (label) |
| Daytime functioning | ✓ | Ask about daytime sleepiness and energy; the trials tracked it and 50 mg improved it |
| Complex sleep behaviors | ✓ | Every visit; stop the drug at the first episode |
| Sleep paralysis, hallucinations, leg weakness | ✓ | Every visit |
| Mood and suicidality | ✓ | Every visit in patients with depression |
| Falls | ✓ | Every visit in older adults |
| Swelling, rash, hives | n/a | Ask early in treatment; stop for any allergic reaction |
| Ongoing need | n/a | Every few months |
If it isn't working
- First, check: the dose (a patient on 25 mg without a 25 mg rule has not had the dose with the strongest trial evidence), the timing (within 30 minutes of bed, not on a full stomach), 7 hours in bed, and any new CYP3A4 inducer such as carbamazepine, rifampin or efavirenz.
- At 7 to 10 days: if the insomnia has not remitted, look for the psychiatric or medical illness driving it, as the label asks, including untreated sleep apnea. If the patient is on 25 mg and no 25 mg rule applies, go to 50 mg.
- Do not: go above 50 mg, raise the dose past 25 mg with a moderate CYP3A4 inhibitor or moderate liver impairment, or add a second hypnotic on top.
- Then: when a moderate inhibitor holds the dose at 25 mg, exposure is already raised (diltiazem lifted it 2.4-fold), so the cap is not under-dosing. Offer CBT-I if the patient has not had it, or change class (low-dose doxepin; ramelteon, but not with fluvoxamine). There are no data on whether a patient who fails one DORA responds to another.
Part 6: Side Effects and How to Manage Them
Overall adverse event rates in the 3-month trials were close to placebo: 38% on 50 mg and 25 mg versus 34% on placebo in Study 1, with nasopharyngitis and headache most common. The rates below come from the label's Study 1 table.
Headache
Headache was the most common adverse reaction: 6% on 25 mg and 7% on 50 mg versus 5% on placebo.
Somnolence and Fatigue
Somnolence or fatigue occurred in 6% on 25 mg and 5% on 50 mg versus 4% on placebo. The label notes it became more likely with age. In the older-adult analysis, patients on 50 mg rated their morning sleepiness better than at baseline (Fietze et al., Drugs Aging 2022).
- Management: enforce the 7-hour rule, move the dose away from dinner, check for alcohol or a new CYP3A4 inhibitor, and drop to 25 mg if sleepiness persists.
Dizziness and Nausea
Dizziness was 2% on 25 mg and 3% on 50 mg versus 2% on placebo. Nausea was 3% on 50 mg versus 2% on placebo and 0% on 25 mg.
Sleep Paralysis, Hallucinations and Cataplexy-Like Symptoms
Sleep paralysis occurred in 0.5% on 25 mg and 0.3% on 50 mg, with none on placebo. Hypnagogic or hypnopompic hallucinations occurred in 0.6% on 25 mg and none on 50 mg or placebo. Cataplexy-like symptoms have been reported with orexin antagonists as a class: leg weakness lasting seconds to minutes, by day or night, sometimes without a trigger.
- Management: explain these before the first dose, as the label asks. Lower the dose or stop if they recur. New weakness with laughter or surprise calls for a narcolepsy evaluation.
Nightmares and Allergic Reactions
After marketing, nightmares or abnormal dreams and hypersensitivity reactions (angioedema, rash, urticaria) have been reported. Hypersensitivity became a contraindication in October 2023, and the label cites angioedema with throat involvement.
Middle-of-the-Night and Next-Morning Function
- Middle of the night: in 36 healthy adults and older adults woken 4 hours after a dose, the ability to wake to a sound was unaffected. Body sway rose by 37 mm on 25 mg and 66 mm on 50 mg over placebo, and word-list recall was worse than on placebo.
- Driving: in 60 healthy adults aged 50 to 79, simulated driving 9 hours after the first dose was significantly impaired on 50 mg and on 100 mg. After 4 nights, the average effect was no longer significant, though some individuals were still impaired. The published report put the first-night increase in lane weaving at 2.19 cm on 50 mg (97.5% CI 0.46 to 3.93) and 4.43 cm on 100 mg, with the 50 mg interval crossing the 2.6 cm impairment threshold (Muehlan et al., Clin Pharmacol Ther 2022).
Daridorexant is a CNS depressant that can impair daytime wakefulness even when taken as prescribed, and the effect may last up to several days after stopping. The label asks you to caution all patients on daridorexant against next-day driving and other activities that need full alertness, with extra care when they took it with less than a full night left or with other sedatives.
Complex Sleep Behaviors
The label carries the class warning: sleepwalking, sleep driving, eating, calls or sex while not fully awake, after the first or any later dose, with or without alcohol. Stop the drug at the first episode. The DORAs do not carry the boxed warning or contraindication the Z-drugs got for this in 2019.
What You Don't See
- Withdrawal: none after 3 months or after 12 months of use (Part 10).
- Interaction with citalopram: no change in exposure or psychomotor performance with citalopram 20 mg.
Part 7: Toxicity, Overdose, and Warnings
Boxed Warning
None. Contraindications are narcolepsy and hypersensitivity to daridorexant or any tablet component. The warnings and precautions are CNS depressant effects and daytime impairment, worsening depression and suicidal ideation, sleep paralysis with hallucinations and cataplexy-like symptoms, complex sleep behaviors, compromised respiratory function, and the need to evaluate for comorbid diagnoses.
Depression and Suicidality
The label notes that people with psychiatric disorders, insomnia included, are at higher risk of suicide, and that hypnotics have been linked to worsening depression and suicidal thoughts and acts in depressed patients. Use it with caution in a patient with depressive symptoms and monitor suicide risk. A disproportionality signal for suicidal ideation in the FDA adverse event database lost significance when daridorexant was compared with other insomnia drugs, and co-reported depression appeared to drive much of it (Sun et al., Soc Psychiatry Psychiatr Epidemiol 2026). Spontaneous-report data cannot settle causation either way.
Abuse and Scheduling
In a human abuse potential study of 63 recreational sedative users, 50 mg produced lower drug liking than zolpidem 30 mg and suvorexant 150 mg, but higher than placebo. At 100 and 150 mg (2 and 3 times the maximum dose), drug liking matched zolpidem and suvorexant. Across 1,232 trial patients treated for up to 12 months, there were no reports suggesting abuse. Animal and clinical data showed no withdrawal on stopping, and the label says this suggests daridorexant does not produce physical dependence. Follow patients with an addiction history closely.
Daridorexant is Schedule IV. On August 11, 2026 the DEA published a proposed rule (91 FR 51606) to move daridorexant, suvorexant and lemborexant to Schedule V. HHS recommended the move. The proposal notes fewer abuse and misuse cases than with zolpidem or temazepam but a number similar to triazolam, possibly because the DORAs are used less, and says the available data suggest the DORAs do not produce physical or psychological dependence. Comments closed September 10, 2026, and no final rule had been published as of November 19, 2026. The proposal also states that DEA denied a 2023 petition from Idorsia to remove the DORAs from control entirely. Prescribe it under Schedule IV rules until a final rule takes effect.
Overdose
Clinical overdose experience is limited. Single doses up to 200 mg (4 times the maximum) in healthy volunteers caused somnolence, muscle weakness, cataplexy-like symptoms, sleep paralysis, poor attention, fatigue, headache and constipation. There is no antidote. Give symptomatic and supportive care with close monitoring, with gastric lavage where appropriate, and consider other drugs on board. Dialysis is unlikely to help because the drug is highly protein bound. The Poison Help line (1-800-222-1222) or a toxicologist can advise. In 51 cases reported to French poison centres (median ingested dose 200 mg), overdoses of daridorexant alone mostly caused somnolence, severe outcomes occurred only when other drugs were also taken, and no one died (von Fabeck et al., Clin Toxicol 2026).
Part 8: Drug Interactions
CYP3A4 does almost all of daridorexant's metabolism, so CYP3A4 drugs set the dose. Daridorexant also nudges up CYP3A4 and P-gp substrates.
| Interaction | Effect | Risk | Action |
|---|---|---|---|
| Strong CYP3A4 inhibitors (itraconazole, clarithromycin, nefazodone) | Itraconazole predicted to raise AUC by more than 400% | HIGH | Avoid |
| Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole, fluvoxamine) | Diltiazem raised AUC 2.4-fold and Cmax 1.4-fold | MODERATE | 25 mg, no more than once per night |
| Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | Rifampin predicted to cut AUC by more than 50% | HIGH | Avoid; efficacy may be lost |
| Moderate CYP3A4 inducers (efavirenz; modafinil per the Dayvigo label) | Efavirenz cut AUC to about 0.4 of baseline | HIGH | Avoid |
| Alcohol | No change in levels, but additive impairment of balance and alertness | HIGH | No alcohol with it |
| Benzodiazepines, opioids, TCAs, other CNS depressants | Additive CNS depression | MODERATE | Use with caution; consider lowering either drug; do not combine with other insomnia drugs |
| Narrow-index CYP3A4 substrates | Midazolam AUC up about 1.4-fold | LOW | Use with caution if the substrate has a narrow therapeutic index |
| Narrow-index P-gp substrates | Dabigatran AUC up about 1.4-fold | LOW | Use with caution if the substrate has a narrow therapeutic index |
| Citalopram, warfarin, rosuvastatin, famotidine | No clinically relevant change in exposure (famotidine lowered peak but not total exposure); no psychomotor interaction with citalopram | NONE | No adjustment |
The label's own examples are itraconazole, diltiazem, rifampin and efavirenz. Clarithromycin, erythromycin, verapamil, fluconazole and fluvoxamine (inhibitors) and carbamazepine and phenytoin (inducers) are from the FDA's table of clinical CYP3A inhibitors and inducers; nefazodone is listed as a strong CYP3A inhibitor in the Belsomra label. The itraconazole and rifampin numbers are predictions from pharmacokinetic modeling; no clinical study measured them.
For a patient on fluvoxamine, daridorexant 25 mg and suvorexant 5 mg both stay within their labels, lemborexant should be avoided, and ramelteon's label says not to combine it with fluvoxamine.
Part 9: Special Populations
Elderly
- Of 1,854 trial patients, 727 (39%) were 65 or older and 110 were 75 or older. The label sets no dose adjustment for age, unlike lemborexant's caution above 5 mg.
- Somnolence and fatigue became more likely with age, and drowsiness raises fall risk, particularly in older adults.
- In the older-adult analysis, 50 mg was needed for the daytime-functioning benefit, and falls were less frequent than on placebo (Fietze et al., Drugs Aging 2022).
- The 2023 AGS Beers Criteria list the Z-drugs and benzodiazepines as hypnotics to avoid in older adults. The orexin antagonists do not appear in them.
Pregnancy
There are no human data. Rats and rabbits showed no malformations or fetal toxicity at up to 8 and 10 times the maximum human exposure. CBT-I comes first in pregnancy; if a hypnotic is needed, agents with more human data are usually preferred, and a patient already stable on daridorexant needs an individual decision. The label says a pregnancy exposure registry will monitor outcomes (Idorsia, 1-833-400-9611).
Lactation
In 10 lactating women given one 50 mg dose, the estimated infant dose was 0.0016 mg/kg/day, a relative infant dose of 0.22%, and 87% of the drug in milk appeared within 24 hours. Levels at steady state should be similar. There are no data on the breastfed infant or on milk production. If used, watch the infant for excess sedation.
Renal Impairment
No adjustment. Severe impairment (creatinine clearance under 30 mL/min, not on dialysis) had no clinically significant effect on exposure.
Hepatic Impairment
- Mild: no change in exposure; usual dosing.
- Moderate (Child-Pugh 7 to 9): unbound exposure rose about 1.6-fold; 25 mg maximum.
- Severe (Child-Pugh 10 or more): not studied; not recommended.
Sleep Apnea and COPD
Five nights of 50 mg did not meaningfully change the apnea-hypopnea index in mild to moderate OSA (25 patients; difference 0.74 events per hour) or severe OSA (16 patients; difference -3.74), in people not using CPAP. Oxygen saturation in moderate COPD was unchanged (25 patients; difference 0.18%). In the severe OSA study, which enrolled people without insomnia, total sleep time rose by about 32 minutes (Fietze et al., Sleep 2026). Mild and severe COPD were not studied, and the label says meaningful respiratory effects cannot be excluded, especially with long-term use. Treat the apnea itself; a hypnotic does not replace CPAP.
Pediatric
Safety and effectiveness have not been established. Use under 18 is off-label.
Part 10: Discontinuation
Daridorexant can be stopped without a taper. No withdrawal symptoms appeared on stopping after 3 months or after a year, and the extension found no rebound. The label sets no taper; stopping directly is practice based on those data.
- Expect the insomnia to come back quickly. On the first night off 50 mg, wake after sleep onset rose by 25 minutes and sleep onset by 16 minutes compared with the last night on drug, and total sleep fell by about 14 minutes a night over the following week. Patients kept on placebo throughout barely changed. That is loss of benefit, and the label reports it separately from withdrawal.
- Carryover is short. The half-life is about 8 hours, though the label still allows that CNS depressant effects may linger for several days in some patients.
- Switching to another DORA: there are no data. Do not overlap them; the label advises against combining insomnia drugs.
- Switching onto daridorexant from a Z-drug, benzodiazepine or trazodone is covered in Part 4.
Part 11: Daridorexant vs the Alternatives
The Three Orexin Antagonists
No head-to-head trials compare the three DORAs. The table sets their US labels side by side.
| Feature | Suvorexant (Belsomra) | Lemborexant (Dayvigo) | Daridorexant (Quviviq) |
|---|---|---|---|
| US approval | 2014 | 2019 | 2022 |
| Tablets | 5, 10, 15, 20 mg | 5, 10 mg | 25, 50 mg |
| Label dose | 10 mg; maximum 20 mg | 5 mg; maximum 10 mg | 25 to 50 mg; maximum 50 mg |
| When to take | Within 30 minutes of bed, 7 or more hours before waking | Immediately before bed, 7 or more hours before waking | Within 30 minutes of bed, 7 or more hours before waking |
| Half-life | About 12 hours | Effective 17 hours (5 mg) and 19 hours (10 mg); active metabolite M10 | About 8 hours |
| High-fat meal | Peak delayed about 1.5 hours; exposure unchanged | Peak delayed 2 hours; Cmax down 23%, AUC up 18% | Peak delayed 1.3 hours; Cmax down 16%; AUC unchanged |
| Strong CYP3A inhibitor | Not recommended | Avoid | Avoid |
| Moderate CYP3A inhibitor | 5 mg; may raise to 10 mg | Avoid | 25 mg maximum |
| Weak CYP3A inhibitor | No label limit | 5 mg maximum | No label limit |
| CYP3A inducers | Strong: efficacy may be reduced | Avoid strong or moderate | Avoid strong or moderate |
| Effect on other drugs | Digoxin rises slightly; monitor digoxin levels | Lowers CYP2B6 substrates (bupropion, methadone) | Raises CYP3A4 and P-gp substrates; caution with narrow therapeutic index drugs |
| Hepatic impairment | No change if mild or moderate; severe not recommended | Moderate: 5 mg maximum; severe not recommended | Moderate: 25 mg maximum; severe not recommended |
| Pivotal trials | Two 3-month placebo-controlled trials (20 mg, 15 mg if 65 or older, alongside higher doses) | SUNRISE-1: 1 month, women 55 and older and men 65 and older, beat zolpidem ER 6.25 mg on late-night waking. SUNRISE-2: 6 months placebo-controlled, 12 months total | Two 3-month trials plus a 40-week extension; 50 mg also improved daytime sleepiness scores |
| Next-morning driving (label study, about 9 hours after dosing) | Impaired in some non-elderly subjects after one 20 mg dose | No significant mean impairment; some subjects impaired on 10 mg | Significant impairment after the first 50 mg dose, not after 4 nights; some subjects impaired (driving simulator study) |
| DEA schedule (November 2026) | C-IV; DEA proposed C-V in August 2026, not final | C-IV; DEA proposed C-V in August 2026, not final | C-IV; DEA proposed C-V in August 2026, not final |
| US generic | None marketed | None | None |
Choosing Among the Three
- Sleep onset or maintenance: all three helped both. In network estimates, daridorexant 50 mg had the largest effect on subjective total sleep and lemborexant 10 mg on subjective sleep onset, and daridorexant 25 mg, lemborexant 10 mg and suvorexant were linked to more somnolence than placebo in a sensitivity analysis (Kishi et al., Transl Psychiatry 2025). Cross-trial estimates like these do not pick the drug for a given patient.
- Next-morning risk: the driving row cannot rank the drugs. The three studies used different doses, people and methods (an on-road test for lemborexant, a simulator for daridorexant), and a shorter half-life does not by itself guarantee an unimpaired first morning.
- Older adults: lemborexant has the only active-comparator trial in older adults (SUNRISE-1) and an observational hip-fracture result in its favor against the Z-drugs; daridorexant's older-adult data are a subgroup analysis. Every DORA label warns about falls.
- Liver disease: in moderate impairment, suvorexant needs no dose change, lemborexant is capped at 5 mg and daridorexant at 25 mg; none is recommended in severe impairment.
- Interacting drugs: with a moderate CYP3A inhibitor such as fluvoxamine, diltiazem or fluconazole, use daridorexant 25 mg or suvorexant 5 mg, not lemborexant. Only lemborexant has a cap with weak inhibitors, and only its label warns that it lowers bupropion and methadone. Suvorexant calls for digoxin levels, and daridorexant for caution with narrow-index CYP3A4 and P-gp substrates. With carbamazepine or another strong inducer, none of the three is a good choice.
- Cost and coverage: all three are brand-only in the US, so the formulary often decides more than the pharmacology; check it before you choose (practice, not label).
Daridorexant vs Other Hypnotics
| Comparison | Daridorexant advantage | Alternative advantage |
|---|---|---|
| vs Z-drugs (zolpidem, eszopiclone, zaleplon) | No withdrawal or rebound in a year of trial use; zopiclone (not sold in the US) caused more adverse-event dropouts than daridorexant in the 2022 network meta-analysis; no boxed warning for complex sleep behaviors; not on the Beers avoid list | Cheap generics; long-term efficacy data for eszopiclone; zaleplon is cleared mainly by aldehyde oxidase, so CYP3A drugs matter less |
| vs Lemborexant | Shorter half-life; 25 mg allowed with moderate CYP3A inhibitors; no age-based dose caution; daytime functioning measured in its pivotal trials | Active-comparator data against zolpidem ER in older adults, including late-night waking; long-term efficacy against placebo in the 2022 network meta-analysis |
| vs Low-dose doxepin (Silenor 3 to 6 mg) | Helps sleep onset as well as maintenance | Not a controlled substance; generic; well tolerated in the network meta-analysis, though efficacy data were scarce; Beers flags doxepin only above 6 mg/day and rates the low dose's safety close to placebo |
| vs Ramelteon | Treats sleep maintenance as well as onset; ramelteon showed no material benefit overall in the 2022 network meta-analysis | Not a controlled substance; generic; the cleaner choice when any misuse risk is unacceptable (but not with fluvoxamine) |
| vs Trazodone | FDA-approved for insomnia; 12-month controlled data; no orthostatic hypotension or priapism warnings | Generic and cheap; useful when depression is also being treated; effective acutely in the network meta-analysis, which grouped it with drugs that were poorly tolerated or lacked long-term data |
Against the other two DORAs, daridorexant has the daytime-functioning data and room for a moderate CYP3A4 inhibitor at 25 mg; it lacks lemborexant's active-comparator trial in older adults. It loses on price to every generic hypnotic, and its first-night driving result means the counseling is the same as for the longer-acting DORAs.
The Bedside Cheat Sheet
What it is
- Dual orexin receptor antagonist (OX1R and OX2R); no active metabolite described
- Half-life about 8 h, the shortest of the three DORAs; no accumulation
- Adult insomnia, onset and/or maintenance; Schedule IV (Schedule V proposed August 2026, not final)
- Brand only (Quviviq); no US generic
Starting and dosing
- Tablets 25 mg and 50 mg
- Label range 25 to 50 mg within 30 min of bed, only with 7 or more hours to sleep
- Trial evidence favors 50 mg, older adults included; no age adjustment
- Moderate CYP3A4 inhibitor or moderate liver impairment: 25 mg maximum
- Not on a full stomach; no second dose; no alcohol
Side effects that matter
- Headache 6% to 7% vs 5%; somnolence or fatigue 5% to 6% vs 4%
- First-morning driving impairment at 50 mg; caution every patient
- Sleep paralysis 0.3% to 0.5%; hallucinations; cataplexy-like weakness
- Hypersensitivity including angioedema (contraindication)
- No withdrawal or rebound; insomnia returns quickly on stopping
Don't forget
- Avoid strong CYP3A4 inhibitors and strong or moderate inducers (itraconazole, clarithromycin, rifampin, carbamazepine, efavirenz)
- Moderate inhibitors (diltiazem, verapamil, fluconazole, fluvoxamine): 25 mg
- Caution with narrow-index CYP3A4 and P-gp substrates
- Coming off a nightly benzodiazepine or Z-drug: taper it 10% to 25% a week; do not leave both
- Narcolepsy and hypersensitivity are the contraindications
Judge it by the patient's afternoons as well as their nights. Only 50 mg moved daytime sleepiness in the trials, so a patient who sleeps a little longer on 25 mg but still drags through the day, and has no 25 mg rule, has not yet had the dose behind that result.